Company Overview - Beijing Puxi Pharmaceutical Technology Co., Ltd. (Puxi Pharma) focuses on the field of immune inflammation and aims to be a leader in localized targeted therapies. The company was established in 2016 and emphasizes innovative design and precise localized delivery in treating chronic inflammatory diseases [3][4] - Puxi Pharma has developed a core product, PG-011 (Pumexitin), which includes two formulations: a gel for atopic dermatitis and a nasal spray for allergic rhinitis. The company is also exploring additional indications for Pumexitin [4] Product Pipeline - PG-011 (Pumexitin) Gel: The world's first JAK inhibitor gel for treating atopic dermatitis, with completed Phase III clinical trials for adults and adolescents aged 12 to 17. The company is expanding its indications to include children aged 2 to 11 [4] - PG-011 (Pumexitin) Nasal Spray: The first clinical-stage JAK inhibitor nasal spray for seasonal allergic rhinitis (SAR), currently in Phase III trials for adults. The company is also expanding its indications to include adolescents and adults with perennial allergic rhinitis (PAR) [4] - PG-033 Tablet: A TRPV3 inhibitor in Phase I trials, targeting pruritus associated with neurodermatitis and other conditions with unmet medical needs [5] - PG-018 Tablet: A dual-target JAK1-ROCK inhibitor for autoimmune kidney diseases, currently in Phase I trials, aiming to provide synergistic clinical benefits [5] - PG-040 Eye Drops: A dual-target ROCK-JAK eye drop for glaucoma, expected to offer better neuroprotection compared to traditional therapies [6] Financial Information - For the fiscal year 2024, Puxi Pharma reported net income of RMB 11.22 million, with losses of approximately RMB 178.5 million. The losses for the nine months ending September 30, 2024, and 2025 were RMB 132.6 million and RMB 124.98 million, respectively [7][8][9] Industry Overview - The global autoimmune disease drug market is projected to grow from USD 116.9 billion in 2019 to USD 143.1 billion in 2024, with a CAGR of 4.1%. It is expected to reach USD 179.5 billion by 2028 and USD 217 billion by 2033 [10] - The Chinese autoimmune disease drug market is expected to grow from RMB 16.2 billion in 2019 to RMB 32.8 billion in 2024, with a CAGR of 15.1%. Projections indicate it will reach RMB 87 billion by 2028 and RMB 219.6 billion by 2033 [13] - The global allergy disease drug market is anticipated to increase from USD 45.5 billion in 2019 to USD 68.8 billion in 2024, with a CAGR of 8.6%. It is expected to reach USD 98.5 billion by 2028 and USD 131.1 billion by 2033 [15] - The Chinese allergy disease drug market is projected to grow from RMB 30.5 billion in 2019 to RMB 57.5 billion in 2024, with a CAGR of 13.5%. It is expected to reach RMB 108.9 billion by 2028 and RMB 293.8 billion by 2033 [17]
普祺医药递表港交所 核心产品普美昔替尼凝胶已完成III期临床试验
Zhi Tong Cai Jing·2026-01-22 03:37